Cognizant announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, has surpassed 250,000 users across 100 countries.
This digital platform facilitates research and collaboration around the globe by allowing clinical study documents and safety notifications to be easily and securely exchanged across site and sponsor teams, Cognizant said.
SIP was established in 2016 as part of a joint effort between Cognizant and TransCelerate, a consortium of the world’s largest biopharmaceutical organizations, to standardize clinical trial documents, training and start-up activities into a single shared environment to reduce costs and increase efficiency.
Today, SIP is in use by 7 of the largest global biopharmaceutical companies, including Merck. Currently in operation at over 32,000 trial-ready sites, SIP’s utilization has increased by more than 65 percent in the last two years.
SIP has been crucial in connecting clinical trial sponsors and research sites, leveraging automation and remote access technology. SIP helped reduce feasibility questionnaire completion times by 36 percent, allowing clinical trials to begin more quickly and thereby helping accelerate the time to market for new therapeutics.